{"id":30855,"date":"2025-07-14T20:24:42","date_gmt":"2025-07-14T20:24:42","guid":{"rendered":"https:\/\/lifestylemedicine.org\/?page_id=30855"},"modified":"2025-11-10T15:45:35","modified_gmt":"2025-11-10T15:45:35","slug":"type-2-diabetes-remission","status":"publish","type":"page","link":"https:\/\/lifestylemedicine.org\/type-2-diabetes-remission\/","title":{"rendered":"Type 2 Diabetes Remission"},"content":{"rendered":"\n
\n\t
\n
\n
\n
\n\n
\n \"\" \"\" <\/div>\n \n
\n
\n

Type 2 Diabetes Remission Is Possible<\/p>\n

Empowering clinicians and patients to achieve remission through lifestyle medicine<\/p>\n <\/div>\n <\/div>\n \n <\/div>\n\n

\n\n
\n \"\" \"\" <\/div>\n \n
\n
\n

Redefining the Standard of Care<\/p>\n

From symptom management to root-cause treatment<\/p>\n <\/div>\n <\/div>\n \n <\/div>\n\n

\n\n
\n \"\" \"\" <\/div>\n \n
\n
\n

Research That Redefines What\u2019s Possible<\/p>\n

Demonstrating that lifestyle interventions can achieve remission and reverse insulin resistance<\/p>\n <\/div>\n <\/div>\n \n <\/div>\n\n

\n\n
\n \"\" \"\" <\/div>\n \n
\n
\n

Advancing Access to Remission-Based Care<\/p>\n

Education, reimbursement, and equity in lifestyle medicine<\/p>\n <\/div>\n <\/div>\n \n <\/div>\n\n <\/div>\n \n<\/div>\n

\n
\n

\n The need to reduce the prevalence of diabetes is urgent <\/h2>\n
\n

Type 2 diabetes (T2D) impacts around 11.6% of adults in the United States, with an increasing occurrence among younger age groups and roughly 23% of those with diabetes go undiagnosed.<\/p>\n

The overall expense of diabetes annually is approximated at $412.9 billion ($306 billion in direct expenses and $106.3 billion in reduced productivity). From both a public health and healthcare expenditure viewpoint, it is a crucial urgency to diminish the prevalence of T2D. Achieving remission, should be a primary goal.<\/p>\n <\/div>\n <\/div>\n<\/div>\n\t<\/div>\n\n \n\n\t<\/section>\n\n\n\n

\n
\n\n \n

Newsflash: New ICD-10 Code Recognizes Type 2 Diabetes Remission<\/h2>

A major milestone for lifestyle medicine<\/h3>\n

\u00a0The 2025 ICD-10 update introduces E11.A \u2014 Type 2 diabetes in remission, enabling clinicians to document remission achieved through lifestyle intervention or other therapies.<\/p>\n

Read the Guidelines (Scroll to page 40)<\/a><\/p>\n<\/div>\n \n <\/div>\n <\/section>\n\n\n\n

\n

Lifestyle medicine is a solution<\/h2><\/div>
\n
\n \"\" <\/div>\n \n
\n\n \n

Clinical Approach<\/p>

Intensive therapeutic lifestyle change<\/p>\n

Research indicates that sufficiently intensive lifestyle intervention, particularly adopting a predominantly whole-food, plant-based dietary pattern, exercise, and sleep, may be comparable to bariatric surgery, a commonly recognized means of effectively achieving T2D remission, but without the potential for side effects.<\/p>\n

Furthermore, studies have shown that the approach advocated by lifestyle medicine physicians can often reduce or eliminate the need for prescription medications, including insulin.<\/p>\n<\/div>\n \n \n \n <\/div>\n <\/div>\n\n \n <\/section>\n\n\n\n

\n
\n
\n

Redefining standards of care for type 2 diabetes<\/h2>\n

Lifestyle medicine is redefining what\u2019s possible in the treatment and remission of type 2 diabetes. The American College of Lifestyle Medicine (ACLM) offers the tools and training clinicians and institutions need to remain at the forefront and deliver value-based, patient-centered care.<\/p>\n

\n \"\" <\/div>\n <\/div>\n
\n
\n \n \"\"

Groundbreaking clinical guidance<\/strong><\/h4>\n
\n

ACLM\u2019s new clinical practice guideline, published in the American Journal of Lifestyle Medicine, is the first to center therapeutic lifestyle change as a primary strategy to treat and put into remission type 2 diabetes and prediabetes. It offers a detailed, evidence-based roadmap with tools for behavior assessment, coaching, and deprescribing protocols that empower clinicians and patients alike to achieve better outcomes.<\/p>\n

Read the Plain Language Summary<\/a><\/p>\n <\/div>\n \n <\/div>\n

\n \n \"\"

Innovative care models<\/strong><\/h4>\n
\n

Lifestyle medicine shared medical appointments (LMSMAs) elevate therapeutic lifestyle change as the foundation of care. This model enhances clinical efficiency, saves costs and supports care team collaboration, making it ideal for scalable implementation that achieves improved patient outcomes.<\/p>\n

Learn More<\/a><\/p>\n <\/div>\n \n <\/div>\n

\n \n \"\"

Interprofessional education<\/strong><\/h4>\n
\n

Accredited CME\/CE courses in lifestyle medicine and food as medicine equip clinicians and care teams with resources that fill the longstanding gap in lifestyle and behavior change support. Deliver scalable, guideline-aligned, patient-centered care.<\/p>\n

Take a Course<\/a><\/p>\n <\/div>\n \n <\/div>\n

\n \n \"\"

Ethically aligned treatment<\/strong><\/h4>\n
\n

ACLM\u2019s Type 2 Diabetes Bill of Rights ensures patients receive fully informed consent at diagnosis, supporting transparency in care decisions and reinforcing the right to access lifestyle-focused, remission-based treatment options.<\/p>\n

Bill of Rights<\/a><\/p>\n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n\n\n

\n
\n\n
\n

Remission of Type 2 Diabetes<\/h2>\n

The American College of Lifestyle Medicine (ACLM) is leading groundbreaking research that demonstrates the power of lifestyle interventions to treat type 2 diabetes and reverse insulin resistance. By focusing on intensive, evidence-based approaches, ACLM\u2019s studies show that many individuals can significantly reduce or eliminate their need for diabetic medications. This research not only supports lifestyle medicine as a frontline therapy but also challenges the conventional narrative that Type 2 diabetes is a lifelong, progressive condition. ACLM continues to build the evidence base to inform clinical guidelines and empower healthcare professionals to deliver high-impact, root-cause care.<\/p>\n <\/div>\n \n

\n
\n